Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Investigating the Efficacy of VELCADE®, Rituximab, Cyclophosphamide and Decadron (VRCD Regimen) in Front-line Therapy of Patients With Low-grade Non-Hodgkin's Lymphoma

NCT00413959 is registered in ClinicalTrials.gov with Oncology Specialists, S.C. as lead sponsor.

NCT NCT00413959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00413959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Investigating the Efficacy of VELCADE®, Rituximab, Cyclophosphamide and Decadron (VRCD Regimen) in Front-line Therapy of Patients With Low-grade Non-Hodgkin's Lymphoma
Lead sponsor
Oncology Specialists, S.C.
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2006
Completion date
January 31, 2011
Enrollment
12 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, b-cell, lymphoma, non-hodgkin